Document:

Stock Purchase Agreement, between the Registrant and Thomas MacMahon

 Exhibit 10.6 
 GOLDEN POND HEALTHCARE, INC. 
 STOCK PURCHASE AGREEMENT 
 This Stock Purchase Agreement (this “Agreement”) is made as of July 16, 2007, by and between Golden Pond Healthcare, Inc., a
Delaware corporation (the “Company”), and Thomas MacMahon (“Purchaser”). 
 1. Purchase and Sale of
Stock. Purchaser hereby agrees to purchase from the Company, and the Company hereby agrees to sell to Purchaser, an aggregate of 78,125 shares of Common Stock of the Company (the “Stock”) at a purchase price equal to
$0.001 per share, for an aggregate purchase price of $78.13, payable in cash. The closing hereunder, including payment for and delivery of the Stock shall occur at the offices of the Company immediately following the execution of this Agreement, or
at such other time and place as the parties may mutually agree. 
 2. Limitations on Transfer. Purchaser shall not assign,
hypothecate, donate, encumber or otherwise dispose of any interest in the shares of Stock except in compliance with the provisions herein and applicable securities laws. The Company shall not be required (a) to transfer on its books any shares
of Stock of the Company which shall have been transferred in violation of any of the provisions set forth in this Agreement or (b) to treat as owner of such shares or to accord the right to vote as such owner or to pay dividends to any
transferee to whom such shares shall have been so transferred. Purchaser hereby further acknowledges that Purchaser may be required to hold the Stock purchased hereunder indefinitely. During the period of time during which the Purchaser holds the
Stock, the value of the Stock may increase or decrease, and any risk associated with such Stock and such fluctuation in value shall be borne by the Purchaser. 
 3. Restrictive Legends. All certificates representing the Stock shall have endorsed thereon legends in substantially the following forms (in addition to any other legend which may be required by other
agreements between the parties hereto): 
 “THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR
RESOLD EXCEPT AS PERMITTED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM.” 
 4. Registration Rights. Purchaser (and his assignees and transferees) shall be granted certain registration rights pursuant to a Registration Rights Agreement reasonably acceptable to the Purchaser and
the Company. 
 5. Investment Representations. In connection with the purchase of the Stock, Purchaser represents to the
Company the following: 
 (a) Purchaser is aware of the Company’s business affairs and financial condition and has sufficient information
about the Company to reach an informed and knowledgeable decision to acquire the Stock. Purchaser is purchasing the Stock for investment for Purchaser’s own account only and not with a view to, or for resale in connection with, any
“distribution” thereof within the meaning of the Securities Act of 1933, as amended (the “Act”). 

 (b) Purchaser understands that the shares of Stock have not been registered under the Act by reason of a
specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of Purchaser’s investment intent as expressed herein. 
 (c) Purchaser further acknowledges and understands that the Stock must be held indefinitely unless the Stock is subsequently registered under the Act or an exemption from such registration is available. Purchaser
understands that the certificate evidencing the Stock will be imprinted with a legend which prohibits the transfer of the Stock unless the Stock is registered or such registration is not required in the opinion of counsel for the Company.

 (d) Purchaser warrants and represents that Purchaser is an “accredited investor” as that term is defined in Rule 501 of
Regulation D promulgated by the Securities and Exchange Commission under the Act. 
 (e) Purchaser further warrants and represents that
Purchaser has either (i) preexisting personal or business relationships, with the Company or any of its officers, directors or controlling persons, or (ii) the capacity to protect his own interests in connection with the purchase of the
Stock by virtue of the business or financial expertise of himself or of professional advisors to Purchaser who are unaffiliated with and who are not compensated by the Company or any of its affiliates, directly or indirectly. 
 6. Miscellaneous. 
 (a)
Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent by confirmed telex or facsimile if sent during
normal business hours of the recipient, and if not during normal business hours of the recipient, then on the next business day, (iii) five (5) calendar days after having been sent by registered or certified mail, return receipt requested,
postage prepaid, or (iv) one (1) business day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the other party hereto at
such party’s address hereinafter set forth on the signature page hereof, or at such other address as such party may designate by ten (10) days advance written notice to the other party hereto. 
 (b) Successors and Assigns. This Agreement shall inure to the benefit of the successors and assigns of the Company and, subject to the
restrictions on transfer herein set forth, be binding upon Purchaser, Purchaser’s successors, and assigns. 
 (c) Governing Law;
Venue. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York. The parties agree that any action brought by either party to interpret or enforce any provision of this Agreement shall be
brought in, and each party agrees to, and does hereby, submit to the jurisdiction and venue of, the appropriate state or federal court for the district encompassing the Company’s principal place of business. 
  

 2 

 (d) Further Execution. The parties agree to take all such further action(s) as may reasonably be
necessary to carry out and consummate this Agreement as soon as practicable, and to take whatever steps may be necessary to obtain any governmental approval in connection with or otherwise qualify the issuance of the securities that are the subject
of this Agreement. 
 (e) Entire Agreement; Amendment. This Agreement constitutes the entire agreement between the parties with
respect to the subject matter hereof and supersedes and merges all prior agreements or understandings, whether written or oral. This Agreement may not be amended, modified or revoked, in whole or in part, except by an agreement in writing signed by
each of the parties hereto. 
 (f) Severability. If one or more provisions of this Agreement are held to be unenforceable under
applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (i) such provision shall be excluded from this
Agreement, (ii) the balance of the Agreement shall be interpreted as if such provision were so excluded and (iii) the balance of the Agreement shall be enforceable in accordance with its terms. 
 (g) Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together
shall constitute one instrument. 
 [Signatures on following page] 
  

 3 

 In Witness Whereof, the parties hereto have executed this Agreement as of the day and year first
above written. 
  

			
	GOLDEN POND HEALTHCARE, INC.
		
	By:	 	 /s/ W. Robert Dahl, Jr.

	Name:	 	W. Robert Dahl, Jr.
	Title:	 	Vice President of Strategic Business Development and Vice Chairman of the Board
		
		 	Address:
		 	18 Arrowhead Way
		 	Darien, CT 06820
		
		 	 /s/ Thomas MacMahon

		 	Thomas MacMahon
		
		 	Address:Private Placement Purchase Agreement

 Exhibit 10.7 
 PRIVATE PLACEMENT PURCHASE AGREEMENT 
 THIS PRIVATE PLACEMENT PURCHASE AGREEMENT (this
“Agreement”) made as of this 16th day of July, 2007, by and between GOLDEN POND HEALTHCARE, INC., a Delaware corporation (the “Company”), and PECKSLAND PARTNERS, LLC, a Delaware limited liability
company (the “Purchaser”). 
 WHEREAS, the Company desires to sell, and the Purchaser desires to acquire, in a
private placement (the “Placement”) an aggregate of 4,000,000 warrants (the “Placement Warrants”), each of which are exercisable for one share of common stock of the Company, which Placement Warrants will be
substantially identical to the warrants forming part of the units being issued to the public in a public offering (the “IPO”) pursuant to the terms and conditions set forth in the Company’s registration statement on Form S-1
(as the same may be amended from time to time, the “Registration Statement”), except that (x) the Placement Warrants and the shares of common stock underlying the Placement Warrants will not be registered under the Securities
Act of 1933, as amended (the “Securities Act”), (y) the Placement Warrants will not be subject to redemption, and (z) the Placement Warrants may be exercised on a cashless basis at the election of the Purchaser; and

 WHEREAS, the Placement Warrants will be governed by the Warrant Agreement and the Placement Warrants will be entitled to the
benefits of a Registration Rights Agreement, each of which will be filed as an exhibit to the Registration Statement. 
 NOW,
THEREFORE, for and in consideration of the premises and the mutual covenants hereinafter set forth, the parties hereto do hereby agree as follows: 
  

	 	1.	PURCHASE OF WARRANTS. The Purchaser hereby agrees, directly or through its nominees, to purchase 4,000,000 Placement Warrants at a purchase price of $1.00 per Placement
Warrant for an aggregate purchase price of $4,000,000 (the “Purchase Price”). 

  

	 	2.	CLOSING. The closing of the purchase and sale of the Placement Warrants (the “Closing”) will take place at such time and place as the parties may agree (the
“Closing Date”), but will in no event be later than the date on which the Securities and Exchange Commission (the “SEC”) declares the Registration Statement effective (the “Effective Date”). On the
Effective Date, the Purchaser shall pay the Purchase Price by wire transfer of funds to an account maintained by the Company. Immediately prior to the closing of the IPO, the Company shall deposit the Purchase Price into the trust account described
in the Registration Statement (the “Trust Account”). The certificates for the Placement Warrants shall be delivered to the Escrow Agent, to be defined in the Stock Escrow Agreement to be filed as an exhibit to the Registration
Statement, promptly after the closing of the IPO. 

  

	 	3.	REPRESENTATIONS AND WARRANTIES OF THE PURCHASER. The Purchaser hereby represents and warrants to the Company that: 

  

	 	a.	The Purchaser is an “accredited investor” as that term is defined in Rule 501 of Regulation D promulgated under the Securities Act. 

	 	b.	The Placement Warrants are being acquired for the Purchaser’s own account, only for investment purposes and not with a view to, or for resale in connection with, any
distribution or public offering thereof within the meaning of the Securities Act. 

  

	 	c.	The Purchaser has the full right, power and authority to enter into this Agreement and this Agreement is a valid and legally binding obligation of the Purchaser enforceable against
the Purchaser in accordance with its terms. 

  

	 	d.	The Purchaser acknowledges that the Placement Warrants, and the shares issued upon exercise of the Placement Warrants, will bear a legend in substantially the following form:

 “THESE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE TRANSFERRED OR RESOLD EXCEPT
AS PERMITTED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM.” 
  

	 	4.	WAIVER OF CLAIMS; INDEMNIFICATION. The Purchaser hereby waives any and all rights to assert any present or future claims, including any right of rescission, against the
Company OR Deutsche Bank Securities, Inc. (“Deutsche Bank”) with respect to its purchase of the Placement Warrants, and the Purchaser agrees to indemnify and hold the Company and Deutsche Bank harmless from all losses, damages or
expenses that relate to claims or proceedings brought against the Company or Deutsche Bank by the Purchaser of the Placement Warrants or its transferees, heirs, assigns or any subsequent holders of the Placement Warrants in respect of the
transactions contemplated hereby. 

  

	 	5.	VOTING OF SHARES; WAIVER OF CONVERSION RIGHTS; LOCK-UP. In connection with the vote required to consummate a Business Combination (as defined in the Company’s
Certificate of Incorporation), the Purchaser shall vote any shares of common stock held by the Purchaser in accordance with the majority of the shares of common stock voted by the Company’s public stockholders, and therefore waives any
conversion rights it might have with respect to such shares of common stock. The Placement Warrants will be subject to a lock-up as referred to in the Registration Statement. Subject to certain limited exceptions to be set forth therein, the
Placement Warrants will not be transferable until ninety days following the closing of a Business Combination. 

  

	 	6.	 WAIVER OF CLAIMS AGAINST TRUST ACCOUNT. The Purchaser hereby waives any and all right, title, interest or claim of any kind in or to any distributions from
the Trust Account with respect to any shares of common stock acquired by the Purchaser in connection with the exercise of the Placement Warrants purchased hereby pursuant to this 

	 	 
Agreement (“Claim”) and hereby waives any Claim the undersigned may have in the future as a result of, or arising out of, any contracts or
agreements with the Company and will not seek recourse against the Trust Account for any reason whatsoever, other than with respect to any shares of common stock purchased in the IPO or in the aftermarket held directly or indirectly by it.

  

	 	7.	REGISTRATION RIGHTS. Purchaser (and its assignees and transferees) shall be granted certain registration rights pursuant to a Registration Rights Agreement reasonably
acceptable to the Purchaser and the Company. If the Company does not complete a Business Combination, or if the Company is unable to deliver registered shares of common stock to the Purchaser pursuant to the Registration Rights Agreement upon
exercise of the Placement Warrants during the exercise period therefor, there will be no settlement of the Placement Warrants and the Placement Warrants will expire worthless. 

  

	 	8.	COUNTERPARTS; FACSIMILE. This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and all of which taken
together shall constitute one and the same instrument. This Agreement or any counterpart may be executed via facsimile transmission, and any such executed facsimile copy shall be treated as an original. 

  

	 	9.	GOVERNING LAW. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York. The parties agree that any action brought by
either party to interpret or enforce any provision of this Agreement shall be brought in, and each party agrees to, and does hereby, submit to the jurisdiction and venue of, the appropriate state or federal court for the district encompassing the
Company’s principal place of business. 

 [signatures on following page] 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first written
above. 
  

			
	GOLDEN POND HEALTHCARE, INC.
		
	By:	 	 /s/ Michael C. Litt

	Name:	 	Michael C. Litt
	Title:	 	Chief Financial Officer and Secretary
	
	PECKSLAND PARTNERS, LLC
		
	By:	 	 /s/ W. Robert Dahl, Jr.

	Name:	 	W. Robert Dahl, Jr.
	Title:	 	Managing Member

 [Private Placement Purchase Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00126-of-00352.parquet"}]]